Abbott and WeightWatchers (WW) launched an app Tuesday designed for people with diabetes — all with the goal of helping patients track how food and exercise impacts their blood sugar levels.

People who are members of WW and follow the WW Diabetes-Tailored Plan can now access Abbott’s glucose monitoring system FreeStyle Libre 2 through the company’s app. 

The idea is that patients will have an accessible way to manage glucose levels as they’re embarking on a journey to maintain a healthy weight.

“Clinical data shows that healthy weight loss leads to a reduction of average glucose which is important for people with diabetes,” Dr. Mahmood Kazemi, chief medical officer at Abbott’s diabetes care business, said in a statement. “Through our partnership, members of the WW Diabetes-Tailored Plan can see within one app how food and activity impact their glucose levels with data backed by our FreeStyle Libre 2 system, so they can make healthy lifestyle choices.”

Kazemi added that Abbott and WeightWatchers both draw on their long histories of aiding people in actualizing healthier lives. 

WeightWatchers previously reported that its WW Diabetes-Tailored Plan reduced HbA1c levels by 0.76 and resulted in average body weight loss of 5.7%. It also claimed that, based on a trial the company conducted, the WW Diabetes-Tailored Plan helped decrease diabetes distress — or the overall stress related to the disease — by nearly 10%.

This also marks furthering of the collaboration between the two companies, which partnered on a diabetes-focused program last year. The initiative integrated WW’ diabetes-specific weight management program with Abbott’s FreeStyle Libre continuous glucose monitoring products. 

The newly launched app feature is one of the first results of that collaborative initiative.

“Together, our two trusted brands are helping people living with type 2 diabetes better understand and manage their chronic condition and gain control of their health while still enjoying the foods they love,” said Gary Foster, chief scientific officer at WW, in a statement.

When the partnership was first unveiled, Chris Scoggins, VP of commercial operations and marketing at Abbott’s diabetes care business, noted that the company plans to further expand the partnership given that diabetes is a “complex chronic condition” that requires various aspects to treatment — from medication and insulin to exercise.

“We recognize that [continuous glucose monitoring products] CGMs are only one piece of the diabetes care puzzle,” he stated. “That’s where the power of partnership comes in.”